These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 4643245)

  • 61. [Medroxyprogesterone and endometrial adenocarcinoma].
    Serment H; Spitalier JM; Ayme Y; Degiovanni E; Bardin JP
    Bull Fed Soc Gynecol Obstet Lang Fr; 1970; 22(1):93-7. PubMed ID: 5453572
    [No Abstract]   [Full Text] [Related]  

  • 62. [Hormonal treatment of endometrial carcinoma].
    Andreoli C
    Minerva Ginecol; 1976 Apr; 28(4):310-7. PubMed ID: 995321
    [No Abstract]   [Full Text] [Related]  

  • 63. Phase II evaluation of dianhydrogalactitol in the treatment of advanced endometrial adenocarcinoma: a Gynecologic Oncology Group Study.
    Stehman FB; Blessing JA; Delgado G; Louka M
    Cancer Treat Rep; 1983; 67(7-8):737-8. PubMed ID: 6871892
    [No Abstract]   [Full Text] [Related]  

  • 64. [The hormone sensitivity of corpus carcinomas].
    Thiery M
    Verh K Vlaam Acad Geneeskd Belg; 1971; 33(5):488-97. PubMed ID: 5164785
    [No Abstract]   [Full Text] [Related]  

  • 65. Turner's syndrome with endometrial adenocarcinoma and stilbestrol therapy.
    Wilkinson EJ; Friedrich EG; Mattingly RF; Regali JA; Garancis JC
    Obstet Gynecol; 1973 Aug; 42(2):193-200. PubMed ID: 4721406
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Action of progesterone on DNA synthesis in the cancerous endometrium].
    Prianishnikov VA; Bokhman IaV
    Akush Ginekol (Mosk); 1975 Dec; (12):28-30. PubMed ID: 1217613
    [No Abstract]   [Full Text] [Related]  

  • 67. [Treatment of adenocarcinomas of the uterine body with medroxyprogesterone].
    Bonte J; Drochmans A; Lassance M
    Gynecol Obstet (Paris); 1966; 65(2):179-85. PubMed ID: 5942790
    [No Abstract]   [Full Text] [Related]  

  • 68. [Therapy of adenocarcinoma of the endometrium with synthetic progestogens].
    Lanza A; Fedele M; Renzetti ME; Ferraris G
    Minerva Ginecol; 1981 Oct; 33(10):917-36. PubMed ID: 7031519
    [No Abstract]   [Full Text] [Related]  

  • 69. Mitoxantrone in adenocarcinoma of the endometrium: a Southwest Oncology Group Study.
    Hilgers RD; Von Hoff DD; Stephens RL; Boutselis JG; Rivkin SE
    Cancer Treat Rep; 1985 Nov; 69(11):1329-30. PubMed ID: 4092197
    [No Abstract]   [Full Text] [Related]  

  • 70. Medroxyprogesterone in the management of primary and recurrent or metastatic uterine adenocarcinoma.
    Bonte J
    Acta Obstet Gynecol Scand Suppl; 1972; 19():21-4. PubMed ID: 4508284
    [No Abstract]   [Full Text] [Related]  

  • 71. [Cytological check-up on the effectiveness of the hormonal treatment of endometriosis].
    Kopecný J; Kopecná V
    Cesk Gynekol; 1973; 38(1):38-9. PubMed ID: 4729366
    [No Abstract]   [Full Text] [Related]  

  • 72. [Chemotherapy of malignant tumors using massive-dose administration of Endoxan].
    Pigatto JC
    Munch Med Wochenschr; 1967 Oct; 109(40):2082-4. PubMed ID: 4873942
    [No Abstract]   [Full Text] [Related]  

  • 73. Carcinoid tumor metastatic to the cervix and corpus uteri. Report of a case.
    Post RC; Cohen T; Blaustein AU; Shenker L
    Obstet Gynecol; 1966 Feb; 27(2):171-5. PubMed ID: 5909536
    [No Abstract]   [Full Text] [Related]  

  • 74. [Tamoxifen. A new antiestrogen effective against uterine neoplasms].
    Iversen OE; Wilhelmsen S; Segadal E
    Tidsskr Nor Laegeforen; 1982 Jul; 102(19-21):1017-8. PubMed ID: 7164053
    [No Abstract]   [Full Text] [Related]  

  • 75. [Tolerance and clinical effects of ethynodiol diacetate in massive doses (50 to 100 mg per day) in treatment of advanced uterine and ovarian cancer (10 cases of advanced cancer)].
    Soutoul JH; Jabot C; Gallier J; Bertrand J
    Bull Fed Soc Gynecol Obstet Lang Fr; 1969; 21(1):80-2. PubMed ID: 5383890
    [No Abstract]   [Full Text] [Related]  

  • 76. Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: a Gynecologic Oncology Group study.
    Slavik M; Petty WM; Blessing JA; Creasman WT; Homesley HD
    Cancer Treat Rep; 1984 May; 68(5):809-11. PubMed ID: 6722836
    [No Abstract]   [Full Text] [Related]  

  • 77. [Stage classification in carcinoma of the corpus uteri].
    Richter P; Krimmenau R
    Zentralbl Gynakol; 1973 May; 95(18):593-602. PubMed ID: 4717301
    [No Abstract]   [Full Text] [Related]  

  • 78. [Progestational hormones in the treatment of gynecologic cancers].
    Soutoul JH; Lagabrielle V
    Presse Med (1893); 1969 Feb; 77(7):247-9. PubMed ID: 5795418
    [No Abstract]   [Full Text] [Related]  

  • 79. [Adenocarcinoma in the corpus uteri. A retrospective study of 150 patients].
    Philipsen T; Nørgaard M
    Ugeskr Laeger; 1983 Jan; 145(3):147-50. PubMed ID: 6845463
    [No Abstract]   [Full Text] [Related]  

  • 80. Progestogen in recurrenct endometrial carcinoma.
    Mehta A; Shroff M
    Indian J Cancer; 1966 Dec; 3(4):305-9. PubMed ID: 5977884
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.